
## Toshifumi Hibi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5389816/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology, 2014, 146, 85-95.	1.3	753
2	Ulcerative colitis. Nature Reviews Disease Primers, 2020, 6, 74.	30.5	678
3	Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology, 2002, 123, 86-91.	1.3	449
4	Evidence-based clinical practice guidelines for inflammatory bowel disease. Journal of Gastroenterology, 2018, 53, 305-353.	5.1	427
5	Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut, 2012, 61, 241-247.	12.1	291
6	Prevalence of ulcerative colitis and Crohn's disease in Japan. Journal of Gastroenterology, 2009, 44, 659-665.	5.1	227
7	A Randomized, Double-Blind, Sham-Controlled Study of Granulocyte/Monocyte Apheresis for Active Ulcerative Colitis. Gastroenterology, 2008, 135, 400-409.	1.3	197
8	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet, The, 2021, 397, 2372-2384.	13.7	194
9	Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. Journal of Crohn's and Colitis, 2016, 10, 1259-1266.	1.3	182
10	Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflammatory Bowel Diseases, 2012, 18, 803-808.	1.9	180
11	Multicenter Randomized Controlled Trial for the Treatment of Ulcerative Colitis with a Leukocytapheresis Column. Current Pharmaceutical Design, 2003, 9, 307-321.	1.9	176
12	Comparison of Targeted vs Random Biopsies for Surveillance ofÂUlcerative Colitis-Associated Colorectal Cancer. Gastroenterology, 2016, 151, 1122-1130.	1.3	171
13	Novel pathophysiological concepts of inflammatory bowel disease. Journal of Gastroenterology, 2006, 41, 10-16.	5.1	147
14	Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis. Gastroenterology, 2018, 154, 935-947.	1.3	139
15	Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Journal of Gastroenterology, 2014, 49, 283-294.	5.1	130
16	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology, 2020, 158, 537-549.e10.	1.3	130
17	Leukocytapheresis in Ulcerative Colitis: Results of a Multicenter Double-Blind Prospective Case-Control Study with Sham Apheresis as Placebo Treatment. American Journal of Gastroenterology, 2005, 100, 1362-1369.	0.4	127
18	Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis. Gastroenterology, 2015, 149, 1775-1783.e2.	1.3	120

#	Article	IF	CITATIONS
19	An Open-Label Prospective Randomized Multicenter Study Shows Very Rapid Remission of Ulcerative Colitis by Intensive Granulocyte and Monocyte Adsorptive Apheresis as Compared With Routine Weekly Treatment. American Journal of Gastroenterology, 2009, 104, 2990-2995.	0.4	117
20	Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. Journal of Gastroenterology, 2003, 38, 740-746.	5.1	116
21	Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. Journal of Gastroenterology, 2013, 48, 31-72.	5.1	109
22	Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. Journal of Crohn's and Colitis, 2012, 6, 160-173.	1.3	106
23	The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies. Journal of Gastroenterology, 2014, 49, 156-162.	5.1	105
24	Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. Journal of Crohn's and Colitis, 2017, 11, 84-91.	1.3	100
25	Adsorptive granulocyte and monocyte apheresis for refractory Crohn?s disease: an open multicenter prospective study. Journal of Gastroenterology, 2004, 39, 1158-1164.	5.1	98
26	A Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene, Encoding a Prostaglandin Transporter. PLoS Genetics, 2015, 11, e1005581.	3.5	94
27	First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis. Journal of Gastroenterology, 2016, 51, 241-251.	5.1	93
28	Disability in inflammatory bowel diseases: Developing ICF core sets for patients with inflammatory bowel diseases based on the international classification of functioning, disability, and health. Inflammatory Bowel Diseases, 2010, 16, 15-22.	1.9	88
29	Adalimumab for the Treatment of Japanese Patients With Intestinal Behçet's Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 940-948.e3.	4.4	86
30	Measurement of Colonic Mucosal Concentrations of 5-Aminosalicylic Acid Is Useful for Estimating Its Therapeutic Efficacy in Distal Ulcerative Colitis: Comparison of Orally Administered Mesalamine and Sulfasalazine. Inflammatory Bowel Diseases, 2001, 7, 221-225.	1.9	82
31	Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflammatory Bowel Diseases, 2008, 14, 1259-1264.	1.9	82
32	Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis. Digestive Diseases and Sciences, 2018, 63, 1910-1919.	2.3	78
33	Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease. Medicine (United States), 2016, 95, e3863.	1.0	77
34	Circulating autoantibodies against purified colonic mucin in ulcerative colitis. Journal of Gastroenterology, 2000, 35, 20-27.	5.1	64
35	Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). Journal of Gastroenterology, 2017, 52, 1101-1111.	5.1	60
36	The Burden of Diverticular Disease and Its Complications: West versus East. Inflammatory Intestinal Diseases, 2018, 3, 61-68.	1.9	60

#	Article	IF	CITATIONS
37	Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS ONE, 2019, 14, e0212989.	2.5	59
38	Dietary fiber fraction of germinated barley foodstuff attenuated mucosal damage and diarrhea, and accelerated the repair of the colonic mucosa in an experimental colitis. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 160-168.	2.8	58
39	Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa. Journal of Crohn's and Colitis, 2018, 12, 1288-1294.	1.3	58
40	Efficacy of Endoscopic Balloon Dilation for Small Bowel Strictures in Patients With Crohn's Disease: A Nationwide, Multi-centre, Open-label, Prospective Cohort Study. Journal of Crohn's and Colitis, 2018, 12, 394-401.	1.3	56
41	Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflammatory Intestinal Diseases, 2019, 4, 79-96.	1.9	53
42	Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 1373-1383.	3.7	50
43	A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: Treatment outcomes of 847 patients in clinical practice. Journal of Crohn's and Colitis, 2014, 8, 981-991.	1.3	49
44	Lipocalin 2 prevents intestinal inflammation by enhancing phagocytic bacterial clearance in macrophages. Scientific Reports, 2016, 6, 35014.	3.3	49
45	Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. Gastroenterology, 2022, 162, 482-494.	1.3	46
46	Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis. Journal of Crohn's and Colitis, 2016, 10, 828-836.	1.3	42
47	Impact of inflammatory bowel disease on Japanese patients' quality of life: results of a patient questionnaire survey. Journal of Gastroenterology, 2017, 52, 555-567.	5.1	42
48	Clinical features of chronic enteropathy associated with SLCO2A1 gene: a new entity clinically distinct from Crohn's disease. Journal of Gastroenterology, 2018, 53, 907-915.	5.1	42
49	Induction of hepatic stellate cell proliferation by LPS-stimulated peripheral blood mononuclear cells from patients with liver cirrhosis. Journal of Gastroenterology, 2000, 35, 214-220.	5.1	40
50	Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn'sÂDisease. Clinical Gastroenterology and Hepatology, 2018, 16, 542-549.e1.	4.4	40
51	Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission. PLoS ONE, 2015, 10, e0140716.	2.5	40
52	Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. Journal of Gastroenterology, 2010, 45, 1129-1137.	5.1	38
53	Effects of family history on inflammatory bowel disease characteristics in Japanese patients. Journal of Gastroenterology, 2012, 47, 961-968.	5.1	38
54	Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 908-921.e6.	4.4	38

#	Article	IF	CITATIONS
55	AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Gastroenterology and Hepatology, 2022, 7, 648-657.	8.1	38
56	Involvement of herbal medicine as a cause of mesenteric phlebosclerosis: results from a large-scale nationwide survey. Journal of Gastroenterology, 2017, 52, 308-314.	5.1	35
57	Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. Journal of Gastroenterology, 2020, 55, 291-306.	5.1	34
58	Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 429-437.	8.1	34
59	Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial. Intestinal Research, 2017, 15, 395.	2.6	33
60	Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. Journal of Gastroenterology, 2013, 48, 1006-1015.	5.1	32
61	Prominent Steatosis with Hypermetabolism of the Cell Line Permissive for Years of Infection with Hepatitis C Virus. PLoS ONE, 2014, 9, e94460.	2.5	32
62	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intestinal Research, 2018, 16, 4.	2.6	32
63	Augmented levels of gastric mucosal leucocyte activation by infection withcagAgeneâ€positiveHelicobacter pylori. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 294-300.	2.8	31
64	Risk factors for decreased bone mineral density in inflammatory bowel disease: A cross-sectional study. Clinical Nutrition, 2015, 34, 1202-1209.	5.0	31
65	Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey. Journal of Gastroenterology, 2019, 54, 891-896.	5.1	31
66	Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 105-115.e14.	4.4	31
67	Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1102-1111.e5.	4.4	29
68	Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey. Inflammatory Intestinal Diseases, 2020, 5, 27-35.	1.9	29
69	Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 1407-1416.	1.3	28
70	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. Gastroenterology, 2022, 162, 1891-1910.	1.3	28
71	Changes of Proliferative Activity and Phenotypes in Spontaneous Differentiation of a Colon Cancer Cell Line. Japanese Journal of Cancer Research, 1993, 84, 625-632.	1.7	26
72	An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. BMC Gastroenterology, 2015, 15, 163.	2.0	26

#	Article	IF	CITATIONS
73	Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. Journal of Crohn's and Colitis, 2020, 14, 617-623.	1.3	26
74	Predictive Factors of Response to Leukocytapheresis Therapy for Ulcerative Colitis. Therapeutic Apheresis and Dialysis, 1998, 2, 115-119.	0.6	24
75	Is there a role for apheresis in gastrointestinal disorders?. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 200-201.	1.7	24
76	Longâ€ŧerm retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1031-1038.	2.8	24
77	Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet's disease: results from a large real-world observational study. Intestinal Research, 2021, 19, 301-312.	2.6	23
78	Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: Evaluation by rapid turnover proteins, and radiologic and endoscopic findings. Journal of Gastroenterology and Hepatology (Australia), 2001, 16, 763-769.	2.8	22
79	Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies. Intestinal Research, 2017, 15, 475.	2.6	21
80	Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intestinal Research, 2018, 16, 233.	2.6	21
81	Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). Journal of Gastroenterology, 2019, 54, 860-870.	5.1	21
82	Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns? Journal of the Anus, Rectum and Colon, 2020, 4, 1-13.	1.1	21
83	Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. Digestive Diseases and Sciences, 2021, 66, 577-586.	2.3	21
84	Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease. Journal of Crohn's and Colitis, 2016, 10, 1033-1041.	1.3	20
85	2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis. Inflammatory Bowel Diseases, 2017, 23, 822-832.	1.9	20
86	Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. Journal of Gastroenterology, 2018, 53, 494-506.	5.1	20
87	Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial. Intestinal Research, 2018, 16, 494.	2.6	20
88	Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis—Capsule Scoring of Ulcerative Colitis. Inflammatory Bowel Diseases, 2018, 24, 2641-2647.	1.9	19
89	Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. BMC Gastroenterology, 2017, 17, 47.	2.0	18
90	A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's Disease. Journal of Crohn's and Colitis, 2022, 16, 746-756.	1.3	18

#	Article	IF	CITATIONS
91	Efficacy of biologic therapies for biologic-naÃ⁻ve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis. Intestinal Research, 2021, 19, 53-61.	2.6	17
92	Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intestinal Research, 2019, 17, 375-386.	2.6	17
93	Mucosal IL-7-mediated immune responses in chronic colitis-IL-7 transgenic mouse model. Immunologic Research, 1999, 20, 251-259.	2.9	16
94	Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. Journal of Crohn's and Colitis, 2013, 7, e49-e54.	1.3	16
95	Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large cale, Prospective, Observational Study. Therapeutic Apheresis and Dialysis, 2016, 20, 197-204.	0.9	16
96	Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: The impact in steroidâ€free elderly patients. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1485-1491.	2.8	16
97	A Simple 1-Day Colon Capsule Endoscopy Procedure Demonstrated to be a Highly Acceptable Monitoring Tool for Ulcerative Colitis. Inflammatory Bowel Diseases, 2018, 24, 2404-2412.	1.9	16
98	Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. PLoS ONE, 2017, 12, e0185131.	2.5	16
99	Treatment Guidelines in Inflammatory Bowel Disease: The Japanese Perspectives. Digestive Diseases, 2013, 31, 363-367.	1.9	15
100	Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study]. Journal of Crohn's and Colitis, 2019, 13, 1097-1104.	1.3	15
101	Obesity, type 2 diabetes, age, and female gender: significant risk factors in the development of alcoholic liver cirrhosis. Hepatology International, 2013, 7, 280-285.	4.2	14
102	Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytoapheresis Therapy. PLoS ONE, 2015, 10, e0131197.	2.5	14
103	Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 225-232.	2.8	14
104	Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. Journal of Gastroenterology, 2020, 55, 390-400.	5.1	14
105	Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. Intestinal Research, 2021, 19, 95-105.	2.6	14
106	Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intestinal Research, 2019, 17, 504-515.	2.6	14
107	Microvascular disturbances in the colonic mucosa in antibioticâ€associated haemorrhagic colitis: Involvement of platelet aggregation. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 681-685.	2.8	13
108	Efficacy and Safety of Oral Budesonide in Patients with Active Crohn's Disease in Japan: A Multicenter, Double-Blind, Randomized, Parallel-Group Phase 3 Study. Inflammatory Intestinal Diseases, 2017, 2, 154-162.	1.9	13

#	Article	IF	CITATIONS
109	A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1Âyear after leukocytapheresis. Journal of Gastroenterology, 2018, 53, 387-396.	5.1	13
110	Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial. Journal of Gastroenterology, 2021, 56, 147-157.	5.1	13
111	Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study. Intestinal Research, 2021, 19, 408-418.	2.6	13
112	Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. Intestinal Research, 2021, 19, 419-429.	2.6	13
113	The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management. Journal of Crohn's and Colitis, 2017, 11, 1302-1308.	1.3	12
114	Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy. Inflammatory Intestinal Diseases, 2017, 2, 228-235.	1.9	12
115	A nationwide, multi-center, retrospective study of symptomatic small bowel stricture in patients with Crohn's disease. Journal of Gastroenterology, 2020, 55, 615-626.	5.1	12
116	Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease. Intestinal Research, 2018, 16, 609-618.	2.6	12
117	Postâ€marketing analysis for biosimilar CTâ€P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2091-2100.	2.8	11
118	Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2180-2186.	2.8	11
119	Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis. Intestinal Research, 2021, 19, 448-460.	2.6	11
120	Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Journal of Gastroenterology, 2017, 52, 1031-1040.	5.1	10
121	Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 943-950.	2.8	10
122	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Advances in Therapy, 2022, 39, 2342-2364.	2.9	10
123	Cross-sectional small intestinal surveillance of maintenance hemodialysis patients using video capsule endoscopy: SCHEMA study. Endoscopy International Open, 2016, 04, E589-E596.	1.8	9
124	Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study. Intestinal Research, 2017, 15, 368.	2.6	9
125	Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease. PLoS ONE, 2019, 14, e0212404.	2.5	9
126	Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. Intestinal Research, 2023, 21, 110-125.	2.6	9

#	Article	IF	CITATIONS
127	Tissue-type plasminogen activator of colonic mucosa in ulcerative colitis. Digestive Diseases and Sciences, 1992, 37, 307-311.	2.3	8
128	Generation of MHC class I-restricted cytotoxic T cell lines and clones against colonic epithelial cells from ulcerative colitis. Journal of Clinical Immunology, 1999, 19, 77-85.	3.8	8
129	Effect of germinated barley foodstuff administration on mineral utilization in rodents. Journal of Gastroenterology, 2000, 35, 188-194.	5.1	8
130	Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score. Hepatology International, 2012, 6, 744-752.	4.2	8
131	Drug Lag for Inflammatory Bowel Disease Treatments in the East and West. Inflammatory Intestinal Diseases, 2018, 3, 25-31.	1.9	8
132	Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study. Intestinal Research, 2018, 16, 255.	2.6	8
133	Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis. Inflammatory Intestinal Diseases, 2021, 6, 117-122.	1.9	8
134	Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial. Digestion, 2021, 102, 742-752.	2.3	8
135	Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients. Intestinal Research, 2019, 17, 87-93.	2.6	8
136	Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. Intestinal Research, 2018, 16, 168.	2.6	8
137	Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2022, 55, 1320-1329.	3.7	8
138	Lower effectiveness of intravenous steroid treatment for moderateâ€ŧoâ€severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2022, 55, 1569-1580.	3.7	8
139	Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis. Crohn's & Colitis 360, 2022, 4, .	1.1	8
140	HLA class-I-restricted and colon-specific cytotoxic T cells from lamina propria lymphocytes of patients with ulcerative colitis. Journal of Clinical Immunology, 2001, 21, 381-389.	3.8	7
141	Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study. Intestinal Research, 2016, 14, 50.	2.6	7
142	Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy. Journal of Clinical Medicine, 2020, 9, 2286.	2.4	7
143	Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease in Japanese and Korean patients: the OPERA study. Intestinal Research, 2020, 18, 45-55.	2.6	7
144	Comparative, immunological studies on Lymphangiectasia of the small intestine revealed in protein losing gastroenteropathy and Behçet's disease. Gastroenterologia Japonica, 1976, 11, 88-99.	0.3	6

#	Article	IF	CITATIONS
145	A Novel Therapy for Corticosteroid-Dependent or Corticosteroid-Resistant Patients with Ulcerative Colitis. Internal Medicine, 1997, 36, 317-318.	0.7	6
146	Bouveret's syndrome with a concomitant incidental T1 gallbladder cancer. Clinical Journal of Gastroenterology, 2010, 3, 248-253.	0.8	6
147	Continuous low-dose irradiation by I-125 seeds induces apoptosis of gastric cancer cells regardless of histological origin. Cancer Biology and Therapy, 2014, 15, 81-88.	3.4	6
148	Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis. Inflammatory Intestinal Diseases, 2019, 4, 131-143.	1.9	6
149	Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-α Inhibitor Induction Therapy among Patients with Crohn's Disease. Inflammatory Intestinal Diseases, 2020, 5, 78-83.	1.9	6
150	Physician–patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis. Journal of Gastroenterology, 2021, 56, 843-855.	5.1	6
151	Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 81-88.	2.8	6
152	Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials. Intestinal Research, 2020, 18, 56-68.	2.6	6
153	A case of severe cholestatic jaundice with hyperthyroidism successfully treated with methimazole. Clinical Journal of Gastroenterology, 2009, 2, 315-319.	0.8	5
154	Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. PLoS ONE, 2018, 13, e0201956.	2.5	5
155	Development of algorithms for identifying patients with Crohn's disease in the Japanese health insurance claims database. PLoS ONE, 2021, 16, e0258537.	2.5	5
156	5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis. Intestinal Research, 2018, 16, 635-640.	2.6	5
157	Safety and efficacy of longâ€ŧerm tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1884-1892.	2.8	5
158	Significant changes in intestinal lymphatic system and immune response elicited by Peyer's patch excision in adult rats. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, 63-69.	2.8	4
159	Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease. Inflammatory Intestinal Diseases, 2018, 3, 1-10.	1.9	4
160	Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network). BMJ Open, 2019, 9, e030134.	1.9	4
161	Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine Sâ€methyltransferase inhibition. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2116-2124.	2.8	4
162	Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. Inflammatory Bowel Diseases, 2022, 28, 200-207.	1.9	4

#	Article	IF	CITATIONS
163	Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study. Intestinal Research, 2017, 15, 358.	2.6	4
164	Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases. Digestion, 2022, 103, 169-173.	2.3	4
165	Hemobilia due to biliary intraepithelial neoplasia associated with Zollinger–Ellison syndrome. Clinical Journal of Gastroenterology, 2012, 5, 189-194.	0.8	3
166	Increased DNA-incorporated thiopurine metabolite as a possible mechanism for leukocytopenia through cell apoptosis in inflammatory bowel disease patients with NUDT15 mutation. Journal of Gastroenterology, 2021, 56, 999-1007.	5.1	3
167	Possible Involvement of Tissueâ€Type Plasminogen Activator in Gastric Ulcer Formation —Biochemical Evaluation Using Biopsy Specimens From Gastric Mucosa—. Digestive Endoscopy, 1990, 2, 49-53.	2.3	2
168	Sulfhydryl blocker-induced colitis in the rat: Immunological changes in thymus gland and colonic mucosa. Journal of Gastroenterology and Hepatology (Australia), 1994, 9, 544-550.	2.8	2
169	Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/ Ribavirin Therapy in Chronic Hepatitis C. PLoS ONE, 2015, 10, e0125664.	2.5	2
170	Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease. Drugs in R and D, 2016, 16, 35-43.	2.2	2
171	Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan. BMC Pediatrics, 2019, 19, 351.	1.7	2
172	Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis—one more arrow in the quiver of nonâ€invasive diagnostics. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 403-403.	3.7	2
173	A Case of Crohn's Disease with Cardiac Tamponade Caused by Tuberculous Pericarditis: Assessment of a Rare Phenomenon. Healthcare (Switzerland), 2021, 9, 695.	2.0	2
174	A Case of Multiple Hepatoid Adenocarcinoma in the Duodenum, Ascending, Transverse Colon and Mediastinum. Progress of Digestive Endoscopy(1972), 1998, 52, 74-77.	0.0	2
175	Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. Intestinal Research, 2019, 17, 218-226.	2.6	2
176	A Case of Crohn's Disease which Initially Presented with Diffuse Inflammation in the Rectum and Sigmoid Colon. Digestive Endoscopy, 1993, 5, 169-174.	2.3	1
177	Preventive Medical Examinations for Colorectal Cancer in Japan to Reduce Mortality from Colorectal Cancer. Digestive Endoscopy, 1997, 9, 3-10.	2.3	1
178	Which makes patients happier, surgery or anti-TNF therapy?. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 272-273.	17.8	1
179	Procedure of endoscopic hemostasis using a distal attachment and short clips against upper gastrointestinal bleeding. Progress of Digestive Endoscopy, 2003, 63, 26-28.	0.0	1
180	A case of recurrent simple ulcer after ileocecal resection for which endoscopic treatment with spraying of absolute ethanol was effective. Progress of Digestive Endoscopy, 2003, 62, 126-127.	0.0	1

#	Article	IF	CITATIONS
181	A Case of Left Ovarian Mature Teratoma Penetrating into the Rectum. Progress of Digestive Endoscopy(1972), 1996, 49, 220-221.	0.0	1
182	Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab. Intestinal Research, 2017, 15, 535.	2.6	1
183	Gastric emptying rate in subjects with malocclusion examined by [ <sup>13</sup> C] breath test. Orthodontic Waves, 2014, 73, 1-1.	0.2	Ο
184	A case of gastric mucosal prolapse polyp that was difficult to differentiate from duodenal submucosal tumor. Progress of Digestive Endoscopy, 2016, 88, 106-107.	0.0	0
185	The role of IL-18 on the pathogenesis of Crohn's disease. Japanese Journal of Clinical Immunology, 2000, 23, 607-610.	0.0	0
186	A case of giant colonic lipoma for witch endoscopic therapy was successful. Progress of Digestive Endoscopy, 2001, 58, 116-117.	0.0	0
187	A case of 0-lla esophageal carcinoma in situ developing along the long axis of the esophagus, which was resected endoscopically. Progress of Digestive Endoscopy, 2004, 64, 52-53.	0.0	0
188	A case of early stage gastric cancer spreading to the pyloric ring resected endoscopically. Progress of Digestive Endoscopy, 2004, 64, 70-71.	0.0	0
189	Usefulness of argon plasma coagulation using a double channel endoscope. Progress of Digestive Endoscopy, 2004, 64, 46-47.	0.0	0
190	A case of esophageal intramural pseudodiver ticulosis on the whole esophagus. Progress of Digestive Endoscopy, 2006, 69, 50-51.	0.0	0
191	A case report of cap polyposis with spontaneous remission. Progress of Digestive Endoscopy, 2006, 68, 140-141.	0.0	0
192	Advanced Pancreatic Cancer Successfully Treated with Biweekly Low-Dose Gemcitabine. Annals of Cancer Research and Therapy, 2008, 16, 21-22.	0.3	0
193	A strategy aimed at low risk ESD and Four days clinical pathway for superficial gastric neoplasias. Progress of Digestive Endoscopy, 2008, 73, 58-61.	0.0	0
194	Intestinal macrophage, "a double-edged sword" for homeostasis and inflammation in the gut. Inflammation and Regeneration, 2010, 30, 412-418.	3.7	0
195	A case of single balloon endoscopy useful for diagnosis of pediatric jejunum ectopic pancreas. Progress of Digestive Endoscopy, 2013, 82, 164-165.	0.0	0
196	A case of idiopathic rectal perforation in a young patient. Progress of Digestive Endoscopy, 2013, 82, 178-179.	0.0	0
197	Magnifying Endoscopic Observation of the Colonic Minute Lesions in Inflammatory Bowel Disease. Progress of Digestive Endoscopy(1972), 1996, 49, 164-165.	0.0	0
198	Two cases of ulcerative colitis which needed emergency surgery for massive hemorrhage and shock Nihon Kyukyu Igakukai Zasshi, 1998, 9, 60-65.	0.0	0

#	Article	IF	CITATIONS
199	A Case of Cytomegalovirus Colitis. Progress of Digestive Endoscopy(1972), 1998, 51, 108-111.	0.0	Ο
200	A case of asymptomatic amoebic colitis localized only in the cecum. Progress of Digestive Endoscopy(1972), 1999, 54, 126-127.	0.0	0
201	A new start for 'Intestinal Research' as an official journal of AOCC. Intestinal Research, 2016, 14, 1.	2.6	Ο
202	PMO-31â€Rapidity of ulcerative colitis symptom improvements during filgotinib induction: phase 2b/3 SELECTION study post-hoc analysis. , 2021, , .		0
203	OMO-2â€Filgotinib efficacy in patients with ulcerative colitis by line of therapy: Phase 2b/3 selection results. , 2021, , .		Ο
204	Usefulness of colestimide for diarrhea in postoperative Crohn's disease. JGH Open, 0, , .	1.6	0